Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

86.52 +1.72 (+2.03%)
Streaming Delayed Price Updated: 12:36 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Slocum Gordon Exits Stake in Kimberly-Clark Worth Nearly $3 Million
Via The Motley Fool
CSX, Intel, Palantir, Nvidia, Merck: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Via Stocktwits
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
From Merck & Co., Inc.
Via Business Wire
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
2 Value Stocks on Our Watchlist and 1 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns. 
Via The Motley Fool
Topics Earnings Intellectual Property
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Investment with Undervalued Potential
Merck & Co. (MRK) is a strong value stock with low P/E, high earnings, stable finances, and a reliable dividend—ideal for long-term investors. 
Via Chartmill
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life'
 
Via Benzinga
3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever
A good stock is an even better buy when it's on sale. 
Via The Motley Fool
Topics Intellectual Property Stocks
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive. 
Via The Motley Fool
Topics Retirement
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
3 Reasons We’re Fans of Merck (MRK)
Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors... 
Via StockStory
Topics Stocks Supply Chain
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x
The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. 
Via Stocktwits
IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups. 
Via Benzinga
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today. 
Via The Motley Fool
Topics Intellectual Property
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
One reliable high-yielder, one dividend growth stock, and one turnaround story for dividend lovers in August. 
Via The Motley Fool
Topics Economy Intellectual Property
2 Cash-Producing Stocks for Long-Term Investors and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Political Tremors Rattle Markets: The Profound Impact of U.S. Elections and Tariff Shocks
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on... 
Via MarketMinute
Topics Economy Government Stocks
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
MERCK & CO. INC. (NYSE:MRK): A Top Dividend Stock with Strong Profitability and Financial Stability
Merck & Co. (MRK) is a top dividend stock with a 4.06% yield, strong profitability, and solid financials, making it a reliable choice for income investors. 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning. 
Via The Motley Fool
Topics Stocks World Trade
Merck (MRK) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows
If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.